MeiraGTx Holdings plc
MGTX
Updated: 23/09/2026, 03:04:30
MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular diseases like inherited forms of blindness, as well as xerostomia (dry mouth) that often follows radiation treatment for head and neck cancers. The company also targets various degenerative and neurodegenerative disorders, notably amyotrophic lateral sclerosis (ALS) and Parkinson's disease. Currently, several of its programs are in active clinical development, including Phase 1/2 trials for Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, radiation-induced Xerostomia, and Parkinson's. MeiraGTx is also preparing to commence a clinical program for xerostomia linked to Sjogren's syndrome and maintains preclinical initiatives for other neurodegenerative conditions. A key collaboration exists with Janssen Pharmaceuticals, Inc. to advance regulatable gene therapy treatments, leveraging MeiraGTx's proprietary riboswitch technology. Established in 2015, MeiraGTx Holdings plc is headquartered in New York, New York.
No summaries found.
- Share price
- $12.35
- Market cap
- $1.14B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Alexandria Forbes
- Employees
- 393
- IPO date
- 08/06/2018
- Beta
- 1.273
- Last dividend
- $0.00
- Day range
- $12.18 – $13.24
- 52-week range
- $6.62 – $15.35
- 1-day performance
- -5.58%
- 1-year performance
- 86.56%
- Current drawdown (1Y)
- -19.54%
- CIK
- 0001735438
- CUSIP
- G59665102
- ISIN
- KYG596651029
- Created
- 07/12/2025, 05:14:25
- Last update
- 23/09/2026, 03:04:30
Track MeiraGTx Holdings plc with an AI analyst
See which prediction-market events move MGTX, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
MeiraGTx Holdings plc (MGTX) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 05/06/2026, 18:32:55
MeiraGTx Holdings plc (MGTX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 15/05/2026, 06:30:45
MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire • STOCK • 14/05/2026, 18:30:00
MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Lags Revenue Estimates
Zacks Investment Research • STOCK • 14/05/2026, 12:10:25
Will MeiraGTx Holdings PLC (MGTX) Report Negative Q1 Earnings? What You Should Know
Zacks Investment Research • STOCK • 05/05/2026, 13:00:32
MeiraGTx (MGTX) Soars 6.8%: Is Further Upside Left in the Stock?
Zacks Investment Research • STOCK • 20/04/2026, 09:55:15
MeiraGTx Holdings plc (MGTX) Discusses 3-Year Phase I Data on AAV-hAQP1 for Radiation-Induced Xerostomia and Commercial Opportunity Transcript
Seeking Alpha • STOCK • 16/04/2026, 19:01:47
MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares
GlobeNewsWire • STOCK • 16/04/2026, 09:47:00
MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)
GlobeNewsWire • STOCK • 16/04/2026, 09:10:00
MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia
GlobeNewsWire • STOCK • 16/04/2026, 09:00:00
MeiraGTx: Turning Dry Mouth Into Liquid Gold
Seeking Alpha • STOCK • 15/04/2026, 15:26:17
MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026
GlobeNewsWire • STOCK • 14/04/2026, 10:30:00